Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | APAF1 | O14727 | 2/20 | 0.34 |
| ▸ | TDP2 | O95551 | 2/20 | 0.34 |
| ▸ | NSD2 | O96028 | 2/20 | 0.34 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triaziquone SCHEMBL8303 | 0.88 | DNMT1 (0.48) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL10906735 | 0.87 | HTT (0.43) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL738610 | 0.87 | DNMT1 (0.42) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL7783197 | 0.86 | MAPT (0.46) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL149876 | 0.86 | MAPT (0.46) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL93807 | 0.86 | DNMT1 (0.37) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL8482977 | 0.86 | DNMT1 (0.37) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL6000230 | 0.86 | DNMT1 (0.47) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL8993238 | 0.86 | DNMT1 (0.47) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL1538515 | 0.86 | DNMT1 (0.47) | DNMT1MAPTHTTTP53STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022268111-A1 | ANTIVIRAL PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 前沿生物药业(南京)股份有限公司 | 2022-12-29 | — | — | WO | claimed |
| EP-3957627-B1 | 6-MEMBERED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SHIONOGI & CO (JP) | 2024-06-19 | — | — | EP | disclosed |
| EP-4219508-B1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVE AND PRODRUG THEREOF | SHIONOGI & CO (JP) | 2024-06-05 | — | — | EP | disclosed |
| EP-4291648-A1 | HYBRID AMEBOCYTE LYSATE AND USES THEREOF | Charles River Laboratories, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| US-11807648-B2 | Process for preparing substituted polycyclic pyridone derivative and crystal thereof | SHIONOGI & CO., LTD. (JP) | 2023-11-07 | — | — | US | disclosed |
| US-20230287004-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | SHIONOGI & CO., LTD. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230258647-A1 | HYBRID AMEBOCYTE LYSATE AND USES THEREOF | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2023-08-17 | — | — | US | disclosed |
| EP-4219508-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVE AND PRODRUG THEREOF | Shionogi & Co., Ltd (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-20230210822-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING FATTY LIVER DISEASE | SHIONOGI & CO., LTD. (JP) | 2023-07-06 | — | — | US | disclosed |
| EP-4194459-A1 | PROCESS FOR PREPARING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVE AND CRYSTAL THEREOF | Shionogi & Co., Ltd (JP) | 2023-06-14 | — | — | EP | disclosed |
| US-5523077-A | CONTAINING BUTHIONINE SULFOXIMINE OR CYSTAMINE AND HYDROQUINONE OR ETHER THEREOF | YALE UNIVERSITY (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0688204-A1 | COMPOSITION AND METHOD FOR WHITENING SKIN | YALE UNIVERSITY (US) | 1995-12-27 | — | — | EP | disclosed |
| WO-1994020068-A1 | COMPOSITION AND METHOD FOR WHITENING SKIN | YALE UNIVERSITY (US) | 1994-09-15 | — | — | WO | disclosed |
| US-5310657-A | Monitoring absorption spectra, analysis of water systems, body fluids | WHITTAKER BIOPRODUCTS, INC. (US) | 1994-05-10 | — | — | US | disclosed |
| EP-0426395-A1 | Kinetic assay for endotoxin using limulus amebocyte lysate and chromogenic substrate | BIOWHITTAKER, INC. (US) | 1991-05-08 | — | — | EP | disclosed |
| EP-0096074-A4 | EXPANDABLE LATTICE OF POLYVINYL ALCOHOL AND POLYETHYLENE GLYCOL. | KEY PHARMA (US) | 1984-05-29 | — | — | EP | disclosed |
| US-4428925-A | LATTICE COATING OF POLYVINYL ALCOHOL AND POLYOXYETHYLENE GLYCOL | KEY PHARMACEUTICALS, INC. (US) | 1984-01-31 | — | — | US | disclosed |
| US-4428926-A | LATTICE COATING OF POLYVINYL ALCOHOL AND POLYOXYETHYLENE GLYCOL | KEY PHARMACEUTICALS, INC. (US) | 1984-01-31 | — | — | US | disclosed |
| EP-0096074-A1 | EXPANDABLE LATTICE OF POLYVINYL ALCOHOL AND POLYETHYLENE GLYCOL | Key Pharmaceuticals, Inc. (US) | 1983-12-21 | — | — | EP | disclosed |
| WO-1983002056-A1 | EXPANDABLE LATTICE OF POLYVINYL ALCOHOL AND POLYETHYLENE GLYCOL | KEY PHARMA (US) | 1983-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807648-B2 | Process for preparing substituted polycyclic pyridone derivative and crystal thereof | REN, C5, PDXK | DNMT1 1010/4885MAPT 3290/4885HTT 2614/4885 |
| US-20230287004-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | C3AR1, NR4A1, HAVCR2 | DNMT1 1796/4885MAPT 4872/4885HTT 4544/4885 |
| US-20230210822-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING FATTY LIVER DISEASE | LIPC, PNLIP, ACACB | DNMT1 4865/4885MAPT 4017/4885HTT 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.